Pathogenesis and treatment of acid peptic disorders: Comparison of proton pump inhibitors with other antiulcer agents

Clinical Therapeutics

Volumn 18, Issue 1, 1996, Pages 2-34

  Sanders, Steven W ^a  

^a TheraTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIULCER AGENT; BETHANECHOL; BICARBONATE; BISMUTH SALT; CALCIUM CARBONATE; CIMETIDINE; CISAPRIDE; DOMPERIDONE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MAGNESIUM HYDROXIDE; METOCLOPRAMIDE; MISOPROSTOL; NIZATIDINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PICOPRAZOLE; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE; UNINDEXED DRUG;

BACTERIAL INFECTION; CLINICAL TRIAL; CONSTIPATION; COST; DIARRHEA; DUODENUM ULCER; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; RECURRENT PEPTIC ULCER; REVIEW; STOMACH ACID SECRETION; STOMACH MUCOSA; STOMACH ULCER; VERTIGO;

EID: 0029816274     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80175-5     Document Type: Article

References (178)

1. Soll AH. Gastric, duodenal, and stress ulcer. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology/ Diagnosis/Management. 5th ed. Philadelphia: WB Saunders: 1989:814-879.
2. Ihamaki T, Varis K, Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Comparison with a computer-matched family sample. Scand J Gastroenterol. 1979;14:801-812.
3. Walsh JH. Acid peptic disorders of the gastrointestinal tract. In: Kelley WN, De-Vita VTJ, eds. Textbook of Internal Medicine. 2nd ed. Philadelphia: JB Lippincott; 1992:500-513.
4. Kurata J, Nogawa A, Watanabe Y, Kawai K. Peptic ulcer disease mortality. Comparison of native Japanese. Japanese Americans, and Caucasian Americans. J Clin Gastroenterol. 1994;18:145-154.
5. 2-receptor antagonists. Am J Med. 1986;81(Suppl 4B):42-48.
6. Von Haunalter G, Chandler VV. Cost of Ulcer Disease in the United States. Project 5894. Palo Alto, Calif: Stanford Research Institute; 1977.
7. Orlando RC. Reflux esophagitis. In: Yamada T, Alpers DH, eds. Textbook of Gastroenterology. Philadelphia: JB Lippincott; 1991:1123-1147.
8. Tytgat GNJ, Rauws EAJ. Campylobacter pylori and its role in peptic ulcer disease. Gastroenterol Clin North Am. 1990;19: 183-196.
9. Dooley CP, McKenna D, Humphreys H, et al. Histological gastritis in duodenal ulcer: Relationship to Campylobacter pylori and effect of ulcer therapy. Am J Gastroentetol. 1988;83:278-282.
10. Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979;91:517-520.
11. Price WE, Grizzle JE, Postlethwait RW, et al. Results of operation for duodenal ulcer. Surg Gynecol Obstet. 1970;131: 233-244.
12. Richardson CT. Gastric ulcer. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. 4th ed. Philadelphia: WB Saunders; 1989:879.
13. Savarino V, Mela GS, Scalabrini P, et al. 24-Hour study of intragastric acidity in duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry. Dig Dis Sci. 1988;33:1077-1080.
14. Merki HS, Fimmel CJ, Walt RP, et al. Pattern of 24-hour intragastric acidity in active duodenal ulcer disease and in healthy controls. Gut. 1988;29:1583-1587.
15. Lichtenberger LM, Graziani LA, Diaql EJ, et al. Role of surface-active phospholipids in gastric cytoprotection. Science. 1983; 219:1327-1329.
16. Macherey HJ, Petersen KU. Rapid decrease in electrical conductance of mammalian duodenal mucosa in vitro. Gastroenterology. 1989;97:1448-1460.
17. Cherry RD, Jabbari M, Goresky CA, et al. Chronic mesenteric vascular insufficiency with gastric ulceration. Gastroenterology. 1986;91:1548-1552.
18. Cronstedt J, Willen R, Balldin G, et al. Gastroduodenal ulceration in abdominal angina. Acta Chir Scand. 1982;148: 687-692.
19. Critchlow J, Magee D, Ito K, et al. Requirements for restitution of the surface epithelium of frog stomach after mucosal injury. Gastroenterology. 1985;88:237-249.
20. Silen W, Ito S. Mechanisms for rapid reepithelialization of the gastric mucosal surface. Ann Rev Physiol. 1985;47: 217-229.
21. Chen MC, Olson C, Tanner M, Soll A. Apical EGF/TGFα receptors mediate enhanced resistance of gastric mucosal cell monolayers to apical acidification. Gastroenterology. 1991;100:42A. Abstract.
22. Chen MC, Lee AT, Soll AH. Mitogenic response of canine fundic epithelial cells in short-term culture to transforming growth factor A and insulin-like growth factor 1. J Clin Invest. 1991;87:1716-1723.
23. Lee AT, Chen MC, Avedian D, Soll AH. Neurocrine and endocrine regulation of canine fundic mucosal epithelial cell growth. Gastroenterolagy. 1991;100: A108. Abstract.
24. Bransom CJ, Boxer ME, Palmer KR, et al. Mucosal cell proliferation in duodenal ulcer and duodenitis. Gut. 1981;22: 277-282.
25. Levi S, Goolad RA, Lee CY, et al. Inhibitory effect of nonsteroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet. 1990;336:840-843.
26. 1 analogue. Gastroenterology. 1986;91:370-378.
27. Flemstrom G, Turnberg LA. Gastroduodenal defence mechanisms. Clin Gastroenterol. 1984;13:327-354.
28. Kahrilas PJ, Gupta RR. The effect of cigarette smoking on salivation and esophageal acid clearance. J Lab Clin Med. 1989;114:431-438.
29. Jaszewski R, Calzada R, Dhar R. Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and entericcoated aspirin. Dig Dis Sci. 1989;34: 1361-1364.
30. 2 output in human subjects. Ann Intern Med. 1987;106:368-371.
31. Kauffman GLJ, Aures D, Grossman MI. Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in dogs. Am J Physiol. 1980;238:G131-G134.
32. Redfern JS, Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: Induction of ulcers by antibodies to prostaglandin. Gastroenterology. 1989;96(Suppl):596-605.
33. Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterolgy. 1988;95:282-294.
34. Collins AJ, Davies J, Dixon AS. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Rheumatol. 1988;27: 106-109.
35. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241-249.
36. Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: Effect of age, race, and socioeconomic status. Gastroenterology. 1991;100:1495-1501.
37. Jones DM, Eldridge J, Fox AJ, et al. Antibody to the gastric campylobacter-like organism - clinical correlations and distribution in the normal population. J Med Microbiol. 1986;22:57-62.
38. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. NEJM. 1989;321:1562-1566.
39. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust. 1985;142:436-439.
40. Koop H, Stumpf M, Bissele R, et al. Antral Campylobacter pylori in different states of gastric acid secretion. Gastroenterology. 1989;96:A267. Abstract.
41. Smoot DT, Mobley HLT, Resau JH. Inhibition of Campylobacter pylori urease activity prevents gastric epithelial cell injury in vitro. Gastroenterology. 1989;96: A480. Abstract.
42. Slomiany BL, Bilski J, Sarosiek J, et al. Campylobacter pylori degrades mucin and undermines gastric mucosal integrity. Biochem Biophys Res Commun. 1987;144: 307-314.
43. Sarosiek J, Slomiany A, VanHorn K, et al. Lipolytic activity of Campylobacter pylori: Effect of sofalcone. Gstroenterology. 1988;96:A399. Abstract.
44. Leunk RD, Johnson PT, David BC, et al. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Micriobiol. 1988;26:93-99.
45. Marshall BJ, Warren JR, Blincow ED, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988;2: 1437-1442.
46. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990;335: 1233-1235.
47. George LL, Barody TJ, Andrews P, et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust. 1990; 153:145-149.
48. Coghlan JG, Humphries H, Dooley C, et al. Campylobacter pylori and recurrence of duodenal ulcers - a 12-month followup study. Lancet. 1987;2:1109-1111.
49. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med. 1992;116:705-708.
50. The Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993;341:1359-1362.
51. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. NEJM. 1991;325:1127-1131.
52. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ. 1991;302:1302-1305.
53. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. NEJM. 1994;330:1267-1271.
54. Aird I, Bewtall HH, Mehigan JA, Roberts JAP. The blood groups in relation to peptic ulceration and carcinoma of colon, rectum, breast, and bronchus. BMJ. 1954;2: 315-316.
55. Ammann RW, Vetter D, Deyhle P, et al. Gastrointestinal involvement in systemic mastocytosis. Gut. 1976;17:107-112.
56. Kumar N, Kumar A, Broor SL, et al. Effect of milk on patients with duodenal ulcers. BMJ. 1986;293:666-667.
57. Kumar N, Vij JC, Sarin SK, Anand BS. Do chilies influence healing of duodenal ulcer? BMJ. 1984;288:1803-1804.
58. Sonnenberg A. Factors which influence the incidence and course of peptic ulcer. Scand J Gastroenterol. 1988;155(Suppl): 119-140.
59. Kahrilas PJ, Hogan WJ. Gastroesophageal reflux disease. In: Sleisenger M, Fordtran J, eds. Gastrointestinal Disease: Pathophysiology/Diagnosis/Management, 5th ed. Philadelphia: WB Saunders; 1993: 378-401.
60. Chiverton SG, Hunt RH. Smoking and duodenal ulcer disease. J Clin Gastroenterol. 1989:11(Suppl):S29-S33.
61. Sontag S, Graham DY, Bessito A, et al. Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. NEJM. 1984;311: 689-693.
62. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. NEJM. 1990; 322:909-916.
63. Muller-Lissner SA. Bile reflux is increased in cigarette smokers. Gastroenterology. 1986;90:1205-1209.
64. Weiner H, Thaler M, Reiser MF, Mirsky IA. Etiology of duodenal ulcer. I. Relation of specific psychological characteristics to rate of gastric secretion (serum pepsinogen). Psychosom Med. 1957;19:1-11.
65. Holtmann G, Armstrong D, Poppel E, et al. Influence of stress on the healing and relapse of duodenal ulcers: A prospective, multicenter trial of 2109 patients with recurrent duodenal ulceration treated with ranitidine. Scand J Gastroenterol. 1992; 27:917-923.
66. Bresnick WH, Rask-Madsen C, Hogan DL, et al. The effect of acute emotional stress on gastric acid secretion in normal subjects and duodenal ulcer patients. J Clin Gastroenterol. 1993;17:117-122.
67. Weiner H. From simplicity to complexity (1950-1990): The case of peptic ulceration - II. Animal studies. Psychosom Med. 1991;53:491-516.
68. Piper DW, McIntosh JH, Ariotti DE, et al. Life events and chronic duodenal ulcer: A case control study. Gut. 1981;22:1101-1107.
69. Gudjonsson B, Spiro HM. Response to placebos in ulcer disease. Am J Med. 1978;65:399-402.
70. Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. NEJM. 1989; 320:69-75.
71. Domschke W, Hagel J, Ruppin H, et al. Antacids and gastric mucosal protection. Scand J Gastroenterol. 1986;21(Suppl 125):144-150.
72. Preclik G, Stange EF, Gerber K, et al. Stimulation of mucosal prostaglandin synthesis in human stomach and duodenum by antacid treatment. Gut. 1989;30: 148-151.
73. Hollander D, Tarnawski A. Are antacids cytoprotective? Gut. 1989;30:145-147.
74. Berstad A, Alexander B, Weberg R, et al. Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes. Gastroenterology. 1988;95:619-624.
75. Marshall BJ, Armstrong JA, Francis GJ, et al. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion. 1983;37 (Suppl 2):16-30.
76. Texter EC. A critical look at the clinical use of antacids in acid-peptic disease and gastric acid rebound. Am J Gastroenterol. 1989;84:97-108.
77. Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. NEJM. 1980;307:400-404.
78. Nagashima R. Development and characteristics of sucralfate. J Clin Gastroenterol. 1981;3(Suppl 2):103-110.
79. Konturek SJ, Brzozowski T, Bielanski W, et al. Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats. Am J Med. 1989;86: 32-37.
80. Szabo S, Hollander D. Pathways of gastrointestinal protection and repair: Mechanisms of action of sucralfate. Am J Med. 1989;86:23-31.
81. 2 metabolism. Am J Med. 1989;86:2-4.
82. Takemoto T, Kimura K, Okita K, et al. Efficacy of sucralfate in the prevention of recurrence of peptic ulcer: Double blind multicenter study with cimetidine. Scand J Gastroenterol. 1987;22(Suppl 140): 49-60.
83. Brandstaetter G, Kratochirl P. Comparison of two sucralfate dosages (2 gms twice a day versus four times a day) in duodenal ulcer healing. Am J Med. 1985;79 (Suppl 2C):36-38.
84. Marks IN, Wright JD, Gilinsky NH, et al. A comparison of sucralfate dosage schedules in duodenal ulcer healing. J Clin Gastroenterol. 1986;8:419-423.
85. Schubert T. Twice daily sucralfate dosing to heal acute duodenal ulcer. Am J Med. 1989;86(Suppl 6A):108-112.
86. Walker JA, Sherman RA, Cody RP. The effect of oral bases on central aluminum absorption. Arch Intern Med. 1990;50: 2037-2039.
87. Garretts JC, Godley PJ, Peterie JD, et al. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother. 1990;34:931-933.
88. Shields HM. Rapid fall of serum phosphorus secondary to antacid therapy. Gastroenterology. 1978;75:1137-1141.
89. Smith AC, Price AB, Borriello P, Levi AJ. A comparison of ranitidine and tripotassium dicitrate-bismuth in relapse rates of duodenal ulcer. The role of Campylobacter pylori. Gastroenterology. 1988;94: A431. Abstract.
90. Szabo S, Vattay P, Scarbrough E, Folkman J. Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate. Am J Med. 1991;91: 158S-160S.
91. Nwokolo CU, Mistry P, Pounder RE. The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate). Aliment Pharmacol Ther. 1990; 4:163-169.
92. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in peptic ulcer disease. Drugs. 1988;36:132-157.
93. Weller MP. Neuropsychiatric symptoms following bismuth intoxication. Postgrad Med J. 1988;64:308-310.
94. Ebell MH. Peptic ulcer disease. Am Fam Physician. 1992;46:217-227.
95. Monk JP, Clissold SP. Misoprostol: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of peptic ulcer disease. Drugs. 1987;33:1-30.
96. Roth S, Agrawal N, Mahowald M, et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med. 1989; 149:775-779.
97. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID induced gastric ulcer with misoprostol: Multicenter, double-blind, placebo controlled trial. Lancet. 1988;2:1277-1280.
98. Thomas JM, Misiewicz G. Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer. Clin Gastroenterol. 1984;13:501-541.
99. 2-receptor antagonists. Standard therapy for acid-peptic diseases. Part II. NEJM. 1990; 323:1749-1755.
100. Hunt RH, Howden CW, Jones DB, et al. The correlation between acid suppression and peptic ulcer healing. Scand J Gastroenterol. 1986;125(Suppl):22-31.
101. McArthur KE, Raufman J-P, Seaman JJ, et al. Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome. Gastroenterology. 1987;93:69-76.
102. 2-receptor antagonists. Dig Dis Sci. 1990;35:976-983.
103. 2-antagonists in the treatment of reflux esophagitis: A critical analysis. Am J Gastroenterol. 1989;98:A130. Abstract.
104. Koelz HR, Birchler A, Bretholz B, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenlerology. 1986;91:1198-1205.
105. Johnson NJ, Boyd EJ, Mills JG, Wood JR. Acute treatment of reflux oesophagitis: A multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther. 1989;3: 259-266.
106. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of the histamine-2 receptor antagonists. Arch Intern Med. 1990;150: 745-751.
107. 2-receptor antagonists: Standard therapy for acid-peptic disease. Part I. NEJM. 1990; 323:1672-1680.
108. McCarthy DM. Ranitidine or cimetidine? Ann Intern Med. 1983;99:551-553. Editorial.
109. 2-receptor blockers. Ann Intern Med. 1991;114: 1027-1034.
110. Maton PN. Omeprazole. NEJM. 1991; 324:965-975.
111. Sharma B, Walt RP, Pounder RE, et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984;25:957-964.
112. Bardhan KD, Bianchi PG, Bose K, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol. 1986;8:408-113.
113. Classen M, Dammann H-G, Domschke W, et al. Omeprazole heals duodenal but not gastric ulcers more rapidly than ranitidine. Hepatogastroenterology. 1985;32:243-245.
114. Archambault A, Pare P, Bailey R, et al. Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. Gastroenterology. 1988;94:1130-1134.
115. Lauritsen K, Rune SJ, Bytzer P, et al. Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. NEJM. 1985;312:958-961.
116. McFarland RJ, Bateson MC, Green JRB, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology. 1990;98:278-283.
117. Valenzuela JE, Berlin RG, Snape WJ, et al. U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group. Dig Dis Sci. 1991;36:761-768.
118. Kager L, Lindberg G, Nilsson LH, et al. The effect of omeprazole and ranitidine on ulcer healing, relief of symptoms, and incidence of adverse events in the treatment of duodenal ulcer patients. Hepatogastroenterology. 1991;38:287-290.
119. Licht H, Andrieu J, Bognel JC, et al. Lansoprazole versus ranitidine dans le traitement des ulceres duodenaux: Resultats d'un essai multicentrique controle, randomise, en double insu sur groupes paralleles. Actual Ther. 1990;19:251-255.
120. Hawkey CJ, Long RG, Bardhan KD, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut. 1993;34:1458-1462.
121. Lanza F, Goff J, Snowcroft C, et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol. 1994;89:1191-1200.
122. Bate CM, Wilkinson SP, Bradby GVH, et al. Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut. 1989;30:1323-1328.
123. Michel P, Lemaire M, Colin R, et al. Short report: Treatment of gastric ulcer with lansoprazole or ranitidine: A multicentre clinical trial. Aliment Pharmacol Ther. 1994;8:119-122. (Erratum appears in Aliment Pharmacol Ther. 1994;8:357.)
124. Bardhan KD, Ahlberg J, Hislop WS, et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther. 1994;8:215-220.
125. Van Deventer G, Cagiola A, Whipple J, et al. Duodenal ulcer healing with omeprazole: A multicenter, double-blind, ranitidine controlled study. Gastroenterolagy. 1988;94:A476. Abstract.
126. Petite JP, Slama JL, Licht H, et al. Comparaison du lansoprazole (30 mg) et de l'oméprazole (20 mg) dans le traitement de l'ulcèr duodénal. Esais thérapeutiques multicentriques comparatif en double aveugle. Gastroenterol Clin Biol. 1993; 17:334-340.
127. Ekström P, Unge P, Carling L, et al. Lansoprazole vs omeprazole in active ulcer: A healing study. Gastroenterology. 1993; 104:74. Abstract.
128. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology. 1994;106:A197. Abstract.
129. Hussein Z, Granneman R, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol. 1993; 36:391-398.
130. Delchier J-C, Isal J-P, Eriksson S, Soule J-C. Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut. 1989;30: 1173-1178.
131. 2-receptor antagonists: A controlled clinical trial. Gut. 1991;32:435-438.
132. Brunner G, Arnold R, Hennig U, Fuchs W. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther. 1993;7(Suppl 1):51-55.
133. Bate CM, Keeling PWN, O'Morain CA, et al. Omeprazole provides faster healing and symptom relief of reflux oesophagitis than cimetidine. Gut. 1989;30:A1493. Abstract.
134. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis: Results of a double-blind, randomized, Scandinaviun multicenter study. Scand J Gastroenterol. 1988;23:625-632.
135. Havelund T, Laursen LS, Skoubu-Kristensen E, Andersen BN. Omeprazole and ranitidine in treatment of reflux oesophagitis: Double blind comparative trial. BMJ. 1988;296:89-92.
136. Bardhan KD, Hawkey CJ, Long R, et al. Lansoprazole versus ranitidine for the treatment of reflux esophagitis. Aliment Pharmacol Ther. 1995;9:145-151.
137. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 1995;9:25-31.
138. Hallerbäck B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology. 1994;107:1305-1311.
139. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994;35:590-598.
140. Lundell L, Backman L, Ekström P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: The efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991; 26:248-256.
141. +-ATPase inhibitor: A controlled, double-blind study. Am J Gastroenterol. 1993;88:1212-1217.
142. Prichard PJ, Yeoman NK, Mihaly GU, et al. Omeprazole: A study of its inhibition of gastric pH and oral pharmacokinetics after morning and evening dosage. Gastroenterology. 1985;88:64-69.
143. +-ATPase inhibitor on gastric pH and serum gastrin. Aliment Pharmacol Ther. 1992;6:359-372.
144. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89:1235-1241.
145. Lefebvre RA, Flouvat B, Kardac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther. 1992; 52:458-463.
146. Karol MD, Mukhergi D, Cavanaugh JH. Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects. Gastroenterology. 1994;106:A103. Abstract.
147. Cavanaugh JH, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on steady-state warfarin metabolism. Gastroenterology. 1991;100:A40. Abstract.
148. 2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther. 1987;31:133-137.
149. Granneman G, Winters EP, Locke CS, et al. Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics. Gastroenterology. 1991; 100:A75. Abstract.
150. Cederberg C, Anderson T, Shankberg I. Omeprazole: Pharmacokinetics and metabolism in man. Scand J Gastroenterol. 1989;166(Suppl):33-40.
151. Flouvat B, Delhotal-Landes B, Cournot A, et al. Pharmacokinetic study of lansoprazole after oral administration to elderly subjects, comparison to young subjects. Eur J Drug Metab Pharmacokinet. 1990;15(Suppl):43. Abstract.
152. Solvell L. The clinical safety of omeprazole. Digestion. 1990;47(Suppl 1):59-63, 76.
153. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther. 1993;7(Suppl 1):56-66.
154. Ekman L, Hansson E, Havu N, et al. Toxicologic studies on omeprazole. Scand J Gastroenterol. 1985;20:53-69.
155. Tielemans Y, Hakanson R, Sundler F, Willems G. Proliferation of enterochromaffin-like cells in omeprazole-treated hypergastrinemic rats. Gastroenterology. 1989;96:723-729.
156. Misawa T, Chijiiwa Y, Imazono Y, et al. Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer. Ther Res. 1991;122:175-189.
157. Ogoshi K, Kato T, Saito S, et al. Clinical study of AG-1749 (lansoprazole): Effects on serum gastrin levels and gastric mucosal ECL cell density. Yakuri Chiryo. 1991;19:933-946.
158. Larsson H, Carlsson E, Hakanson R, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Gastroenterology. 1988;95:1477-1486.
159. Larsson C, Skogseid B, Oberg K, et al. Multiple endocrine neoplasia type I gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988;332:85-87.
160. Metz DC, Pisegna JR, Ringham GL, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci. 1993;38: 245-256.
161. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991;35:490-496.
162. Unge P, Gad A, Eriksson K, et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol. 1993;5:325-331.
163. Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology. 1995;108: 1412-1417.
164. Burette A, Glupczynski Y, Deprez C, Crombez A. Lansoprazole plus roxithromycin and metronidazole for eradication of Helicobacter pylori: Results of a single blind pilot study. Gastroenterology. 1993;104:49. Abstract.
165. Logan RP, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut. 1994;35:323-326.
166. Harris AW, Gummett PA, Logan RPH, et al. Eradication of Helicobacter pylori (Hp) with lansoprazole and clarithromycin. Am J Gastroenterol. 1994;89: 1373. Abstract.
167. Cayla R, Zerbib F, de Mascarel A, et al. High dose of lansoprazole in combination with amoxicillin and clarithromycin twice daily for H. pylori eradication: Results of a pilot study. Am J Gastroenterol. 1994;89:1367.
168. de Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet. 1995;345:817-820.
169. Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: Seven year follow-up. Lancet. 1994;343:258-260.
170. Parente F, Lazzaroni M, Sangaletti O, et al. Short- and long-term outcome of HP positive resistant duodenal ulcers treated with colloidal bismuth subcitrate (CBS) plus antibiotics or sucralfate. Gastroenterology. 1992;102:A142. Abstract.
171. Bieberdorf FA, Walsh JH, Fordtran JS. Effect of optimum therapeutic dose of poldine on acid secretion, gastric acidity, gastric emptying, and serum concentration after a protein meal. Gastroenterology. 1975;68:50-57.
172. Koelz HR. Protective drugs in the treatment of gastroduodenal ulcer disease. Scand J Gastroenterol. 1986;21(Suppl 125):156-164.
173. Van Deventer GM, Schneidman D, Walsh JH. Sucralfate and cimetidine as single agents and in combination for treatment of active duodenal ulcers. A double-blind placebo-controlled trial. Am J Med. 1985; 79:39-44.
174. Arakawa T, Higuchi K, Fukuda T, et al. H122-receptor antagonist-refractory ulcer: Its pathophysiology and treatment. J Clin Gastroenterol. 1991;31(Suppl): 129-133,
175. Bianchi PG, Parente F. Long-term treatment of duodenal ulcer. A review of management options. Drugs. 1991;41:38-51.
176. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Aliment Pharmacol Ther. 1993;7:41-50.
177. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long term treatment with omepruzole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med. 1994;121:161-167.
178. Sampliner R. Effect of up to 3 years of high dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 1994;89: 1844-1848.